Red Light Therapy to Prevent Mouth Sores: What Cancer Patients Should Know About Photobiomodulation

Eighty-two out of eighty-three.

That is how many stem cell transplant patients at one Colorado hospital developed painful mouth sores during a recent year of treatment. Not half of them. Not most of them. All but one.

Vicky Reiser, a hematology nurse practitioner at the University of Colorado Anschutz, counted those cases herself. She works with blood cancer patients going through allogeneic stem cell transplants, the kind where a donor's healthy cells replace a patient's damaged bone marrow. The high-dose chemotherapy that makes the transplant possible also attacks the lining of the mouth and throat. The result is a side effect called oral mucositis: raw cuts, tears, and ulcers that can make it hurt to swallow your own saliva.

Reiser decided her patients deserved better than a near guarantee of that pain. This fall, her project won her hospital's Shark Tank competition for quality improvement ideas, and it secured the funding to bring a red light therapy machine to campus. The therapy has a long name, photobiomodulation, and a simple promise: shine a gentle red light inside the mouth, a few minutes at a time, and far fewer patients develop the worst of these sores.

This is not a brand-new discovery, and it is not a miracle gadget. It is a treatment that expert guidelines have recommended for years, backed by randomized trials, that most patients have simply never been offered because their hospital did not own the machine. Here is what it is, what the evidence actually shows, who it can help, and the honest limits.

First, what are these mouth sores, exactly?

Oral mucositis is one of the most feared side effects of cancer treatment, and Reiser says patients who learn about it often dread it more than nausea. Chemotherapy and radiation go after fast-growing cells. Cancer cells grow fast, but so do the cells lining your mouth and gut. When those lining cells are damaged faster than the body can repair them, the surface breaks down into open ulcers.

The sores usually start as redness and a burning feeling, then turn into painful ulcers on the cheeks, lips, tongue, and throat. Doctors grade them from mild to severe. At the severe end, patients cannot eat or drink enough on their own. Some need a feeding tube through the nose. Others need IV nutrition, called total parenteral nutrition, or TPN. Many need IV pain pumps they control with a button.

If you want the full picture of how these grades work, our guide to the WHO mucositis grading scale walks through each level.

The dangers go beyond pain. The mouth's lining is a barrier. When it breaks open, bacteria can cross into the bloodstream and cause infections that can turn life threatening, especially in transplant patients whose immune systems are at their weakest. Research cited in the Colorado report found that roughly 70% to 86% of stem cell transplant patients develop oral mucositis. Reiser's own count, 82 of 83 patients in fiscal year 2024-25, sits right at the top of that range.

And there is a quieter cost that matters a great deal to us at HuMOLYTE. When your mouth is full of sores, you stop eating. You stop drinking. Weight falls, muscles waste, and recovery slows. That slide into malnutrition is the same territory as cancer cachexia, the weight and muscle loss that makes treatment harder to tolerate. Preventing the sores in the first place protects everything downstream: food, fluids, strength, and the ability to stay on treatment.

A nurse who had seen it work before

Reiser did not discover this therapy in a journal. Years ago, working as a bedside nurse in Pennsylvania, she watched it help patients in person. When she joined CU Anschutz in 2024 and saw how common mucositis was on her transplant unit, she checked whether the therapy was available. It was not, at least not for her adult patients. A children's hospital on the same campus, Children's Hospital Colorado, already offered it to young blood cancer patients, and their team shared what they had learned.

So Reiser built a case. Through a hospital fellowship for quality improvement projects, she put together the funding to buy a photobiomodulation machine from a company called THOR Photomedicine. She won the Department of Medicine's Shark Tank Competition, a contest that funds ideas to improve care and cut costs. She also won a 2026 grant to study the results carefully.

Starting this year, every allogeneic stem cell transplant patient at the hospital will be offered the light therapy four days a week during their chemotherapy treatment. Reiser's team will track whether patients get sores, how severe they get, and whether the therapy reduces infections, feeding support, and pain pump use.

"I saw the prevalence of mucositis among our patients, and I felt a huge need to make photobiomodulation therapy available to them because I knew what a big impact we could make." — Vicky Reiser, DNP

Her hope, if it works as expected, is to buy a second machine and expand to other high-risk patients, like leukemia patients getting intensive chemotherapy.

What is photobiomodulation, in plain English?

Photobiomodulation (foh-toh-by-oh-mod-yoo-LAY-shun) is also called low-level light therapy or red light therapy. A trained nurse or clinician holds a small light device against the outside of your cheeks and uses a mouthpiece, nicknamed an "LED Lollipop," that shines light in several directions inside the mouth at once.

Here is the easiest way to picture how it works. Inside every cell are tiny power plants called mitochondria. They make the energy your cells run on. Red and near-infrared light, at very specific wavelengths, is absorbed by an enzyme in those power plants. Think of it as recharging the cell's batteries. With more energy available, damaged tissue repairs itself faster and inflammation calms down.

It is a bit like sunlight helping a garden grow, except this is one single color of light, at a measured dose, for a measured number of minutes, given by trained staff. That measurement matters, and we will come back to it when we talk about home gadgets.

Despite the old nickname "low-level laser therapy," this is not a laser show and it does not burn. The light is gentle and low intensity. It does not heat or cut tissue. Reiser describes it simply: the light is shined on the cheeks and inside the mouth, it is painless, and a session takes about five minutes.

What the research shows: five findings that matter

A single hospital's project would not mean much on its own. What makes this story different is that the therapy behind it has been studied for decades. Here are the findings worth knowing.

Finding 1: In a placebo-controlled trial, severe mouth sores fell from 40.5% to 6.4%

The landmark trial was published in 2013 by Antunes and colleagues in Radiotherapy and Oncology. Ninety-four patients with head and neck cancer receiving chemotherapy and radiation were randomly assigned to preventive light therapy or a placebo light. Severe mouth sores, the grade 3 to 4 kind that stop you eating, developed in 40.5% of the placebo group but only 6.4% of the light therapy group. Put another way, for roughly every three patients treated, one case of severe mucositis was prevented. The light group also reported better quality of life, including less pain and easier swallowing.

Finding 2: Pooling 22 trials, preventive light cut the risk of severe sores by about 60%

One trial can be a fluke. Pooling many trials is the real test. A 2020 meta-analysis by Peng and colleagues, covering 22 prevention studies with 1,190 patients, found that preventive light therapy reduced the risk of severe oral mucositis by about 60% (a relative risk of 0.40). It also lowered the average severity of sores, reduced severe pain, and, when used as treatment, shortened how long severe sores lasted. An earlier meta-analysis focused on transplant and radiation patients found a nearly identical result, with risk cut by about 63%.

Finding 3: The newest trial, with a modern device, points the same way

In 2026, Hu and colleagues reported a double-blind, sham-controlled trial at 12 US centers using a newer device, a soft silicone mouthpiece called MuReva that delivers light for 10 minutes right before each radiation session. Among head and neck cancer patients, severe mucositis developed in 36.8% of the light group versus 57.1% of the sham group during treatment. Two weeks after treatment ended, the gap was wider: 10.8% versus 36.4%. There were no device-related side effects, and patients completed 99.5% of their sessions.

Finding 4: Expert guidelines recommend it, at their strongest level, in three settings

The MASCC/ISOO guidelines are the worldwide reference for mucositis care, written by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology. Their current guidelines formally recommend photobiomodulation to prevent oral mucositis in three groups:

  • Patients receiving high-dose chemotherapy as conditioning for a stem cell transplant, with or without total body irradiation (strongest level of evidence)
  • Head and neck cancer patients receiving radiation together with chemotherapy (strongest level of evidence)
  • Head and neck cancer patients receiving radiation without chemotherapy

The National Cancer Institute's PDQ summary on oral complications lists the therapy for the transplant group as well, and in March 2026 the Oncology Nursing Society classified it as "recommended for practice."

Just as important is who is not on that list. For patients receiving standard chemotherapy alone, with no transplant and no head and neck radiation, the guideline panel said the evidence was not strong enough to make any recommendation, for or against. If that is your situation, this therapy is a question to raise, not a proven answer.

Finding 5: Long-term follow-up found no sign of harm to cancer outcomes

The fair question with any therapy that helps cells repair is whether it might also help cancer cells. Researchers have tracked this directly. In a study from Belgium, 222 head and neck cancer patients who received light therapy were compared with 139 who did not, and both groups were followed for a median of more than nine years. There was no difference in survival, no difference in the cancer coming back in the same area, and no difference in time without disease progression. A separate review of the safety literature found no evidence that the therapy raises the risk of new cancers or recurrence. Clinicians still use a simple precaution: they do not shine the light directly on an active tumor.

What treatment is actually like

Patients often picture something high-tech and uncomfortable. The reality is closer to a dental checkup.

  • It is given at the cancer center, by nurses or other trained staff, as part of your treatment plan.
  • Transplant patients typically receive it once a day during their hospital stay, starting around the beginning of conditioning chemotherapy. At the Colorado hospital, the plan is four days a week during chemotherapy treatment.
  • Radiation patients typically receive it about three days a week, often right before a radiation session, for roughly 10 to 15 minutes.
  • It does not hurt. The light does not heat the tissue. Most people feel nothing, or at most a mild warmth or tingle. A small number of people in studies reported a brief, non-painful burning feeling.
  • Eye protection is worn during laser-based sessions, because stronger laser light can harm the eyes. The LED versions do not carry the same risk.
  • Timing matters. The best results come from starting early, at the beginning of treatment, before sores form. This is mainly a prevention therapy. The evidence for treating sores that are already severe is much weaker.

Reiser notes that many of her patients in Pennsylvania reported pain relief within minutes of a session. That is her clinical experience rather than a trial result, but it matches the therapy's anti-inflammatory effect.

Four myths to clear up

Myth 1: "It's a laser, so it must burn or damage tissue"

No. The word "laser" in the old name misleads people. These devices use low-intensity light that is absorbed by cells, not heat that cooks them. Across the randomized trials reviewed for the guidelines, no short-term or long-term side effects from the therapy itself were reported. Occasional minor effects, like brief numbness or a sunburned feeling that fades within a day, have been described in nursing reports.

Myth 2: "I can just buy a red light panel online and do this at home"

This is the most important myth to bust. The guideline protocols specify an exact wavelength (in the red range, roughly 633 to 660 nanometers), an exact dose, and an exact schedule. Oncology nurses who run these programs are blunt about the cheap home units sold online: they are not calibrated, and they are not set at the right wavelength. A $35 gadget is not the therapy tested in the trials, the same way a garden hose is not a measured dose of medicine. Their other rule is worth remembering: more is not better. Too much light can actually work against the effect.

Myth 3: "If it helps cells heal, it must feed the cancer"

This worry is understandable, and it has been studied for years, including a follow-up of more than nine years in head and neck cancer patients. The data so far show no difference in survival or recurrence. The therapy is also aimed at the mouth lining, and clinicians avoid shining it on an active tumor. It is fair to ask your team about it. It is not a reason the evidence supports for refusing the therapy.

Myth 4: "It works for mouth sores from any chemotherapy"

Not proven. The strong evidence is in two worlds: transplant conditioning and head and neck radiation, with or without chemotherapy. For standard chemotherapy regimens, the expert panel could not make a recommendation at all. Research in children is also mixed: some pooled analyses of pediatric trials found no clear benefit, even though children's hospitals like the one on the Colorado campus report strong results in their own programs. Honest answer: promising and proven in specific settings, still an open question in others.

Why haven't I heard of this before? The access problem

If this therapy is guideline-recommended and trial-proven, why is a nurse in Colorado making news for getting one machine? Because knowing something works and getting it to patients are two different problems.

The machines cost money. A unit runs about $20,000, plus mouthpieces, cleaning systems, staff training, and the staff time to give treatments every day. Some hospitals, like one Michigan program described by the Oncology Nursing Society, bought their machines with donated funds and offer the therapy to patients at no charge.

Insurance has historically not paid for it. For years there was no billing code for this therapy, so hospitals absorbed the cost. That is slowly changing. The first device made specifically for mouth sores, MuReva, received FDA authorization in November 2025, and a tracking code for the procedure took effect in January 2026. A tracking code lets the health system count how often the therapy is used, but it does not by itself pay for anything. Whether insurers will cover it is still being decided, so in late 2026 the honest summary is: coverage is in flux, and many centers still provide it free or bundled into treatment.

The FDA picture needs one honest footnote. The THOR machines many centers use are FDA-cleared in the United States for pain relief and circulation claims. Using them for mouth sores is what doctors call off-label use, which is legal and common in medicine, but it is not an FDA-cleared indication here. (In the United Kingdom, Europe, and Australia, the same device's approval does include mouth sores.) The MuReva mouthpiece is the first device authorized by the FDA specifically for preventing mouth sores, in adults getting radiation to part of the oral cavity.

Availability is the real limit. Your center either owns a machine and has trained staff, or it does not. That is why Reiser's project matters beyond one hospital. It is a template: a nurse counted the harm, found the evidence, won internal funding, and is tracking the results so the case for the next machine makes itself.

While you wait for access: protecting your mouth, food, and fluids

Whether or not your center offers light therapy, mouth care during treatment is not optional, and small habits make a real difference.

  • Start dental care early. A dental check before treatment, gentle brushing with a soft brush, and regular saltwater or baking soda rinses keep the mouth cleaner and more comfortable.
  • Watch for the early signs. Redness, a burning feeling, or new sensitivity to hot, cold, or spicy foods often come before open sores. Tell your team early, not after a week of pain.
  • Keep eating and drinking, adapted. Soft, cool, moist foods are easier than dry, crunchy, acidic, or spicy ones. Small frequent sips beat big glasses. If swallowing gets hard, ask for a dietitian referral early, before weight starts sliding.
  • Take pain seriously. Pain that stops you eating is a medical problem, not something to push through. Your team has options, from coating rinses to stronger pain control.
  • Hydration and nutrition support matter. When a sore mouth cuts your intake, your body still needs fluids and electrolytes to handle chemotherapy. That is exactly the gap HuMOLYTE was designed to support: gut-friendly hydration and nutrition for people in treatment, in a form that is gentle to get down.

Reiser makes one more point that belongs here. Her team avoids IV nutrition when they can, because when the gut stops being used, it can start to shut down and cause new complications. Keeping your mouth working, so you can keep eating and drinking, protects your gut as well as your weight.

Watch for these: call your team promptly if you notice

  • New mouth redness, burning, or soreness, especially in the first two weeks of treatment
  • Sores or white patches on your cheeks, lips, tongue, or throat
  • Pain that makes it hard to swallow food, fluids, or your own saliva
  • Eating or drinking much less than usual for more than a day
  • Fever, chills, or feeling suddenly unwell while your mouth is sore (possible infection)
  • Signs of dehydration: very dry mouth, dizziness, dark urine, or urinating much less
  • Weight dropping week to week

Questions to ask your oncology team

  1. Does my treatment plan put me at high risk for mouth sores?
  2. Does this center offer photobiomodulation (red light therapy) for preventing mouth sores?
  3. If not here, is there a center nearby that offers it, and would a referral make sense?
  4. Am I in one of the groups the guidelines recommend it for: transplant conditioning, or head and neck radiation with or without chemotherapy?
  5. When would I start, and how often would I receive it during my treatment?
  6. What will it cost me? Is it billed to insurance, bundled, or provided at no charge?
  7. If light therapy is not available, what is our prevention plan for mouth sores instead?
  8. What mouth care routine should I follow at home during treatment?
  9. At what point would we consider a feeding tube or IV nutrition, and how do we avoid getting there?
  10. Who do I call, day or night, if mouth pain stops me from eating or drinking?

The bottom line

  • At one Colorado hospital, 82 of 83 transplant patients developed mouth sores in a year. A nurse practitioner, Vicky Reiser, won funding to do something about it: a red light therapy machine for every transplant patient, starting this year.
  • The therapy, photobiomodulation, uses gentle red light to recharge cell repair and calm inflammation. Sessions take about 5 to 15 minutes, do not hurt, and are given several times a week during treatment.
  • In trials, preventive light therapy cut severe mouth sores dramatically: from 40.5% to 6.4% in a placebo-controlled trial, and by about 60% across pooled studies.
  • International guidelines recommend it, at their strongest level, for transplant patients and for head and neck radiation patients. For standard chemotherapy alone, the evidence is not yet strong enough for a recommendation.
  • Follow-up lasting more than nine years found no sign that it harms cancer outcomes.
  • The catch is access, not evidence. Machines cost about $20,000, insurance coverage is still unsettled, and many centers do not offer it yet. Asking your team whether it is available is the first step.

Frequently asked questions

Does red light therapy for mouth sores hurt?

No. The light is low intensity and does not heat or burn tissue. Most patients feel nothing. Some feel mild warmth or tingling, and a small number report a brief, non-painful burning sensation. Sessions take about 5 to 15 minutes.

Is photobiomodulation the same as the red light panels sold for home use?

No. The therapy tested in trials uses a specific wavelength, a measured dose, and a set schedule, delivered by trained staff at a cancer center. Home gadgets are not calibrated to those protocols, and oncology nurses specifically warn against assuming they deliver the same treatment.

Who benefits most from this therapy?

Patients at highest risk of severe mouth sores: those receiving high-dose chemotherapy for a stem cell transplant, and those receiving radiation for head and neck cancer, with or without chemotherapy. Those are the groups the MASCC/ISOO guidelines recommend it for.

Can it treat mouth sores I already have?

The strong evidence is for prevention, starting early in treatment before sores become severe. Evidence for treating sores that have already formed is weaker. If you already have sores, ask your team about the full range of options, including pain control and mouth care.

Is it FDA approved for mouth sores?

One device, the MuReva mouthpiece, was authorized by the FDA in November 2025 specifically for preventing mouth sores in adults receiving radiation to part of the oral cavity. The THOR devices used by many centers are FDA-cleared for pain relief claims, and their use for mouth sores is off-label in the United States, though approved for that use in the UK, Europe, and Australia.

Will insurance pay for it?

Often not yet, and it varies. A tracking code for the procedure began in January 2026, but it does not itself pay. Some centers bought machines with donated funds and provide the therapy at no charge. Ask your center directly what it would cost you.

Could the light make my cancer worse?

This has been studied directly. In head and neck cancer patients followed for a median of more than nine years, those who received the therapy had the same survival and the same recurrence rates as those who did not. Clinicians also avoid shining the light on an active tumor, as a precaution.

Sources

1 CU Anschutz Newsroom, "CU Anschutz Faculty Secures Red Light Therapy Machine to Help Prevent Painful Ulcers in Blood Cancer Patients," November 17, 2026 2 Elad S et al., "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy," Cancer, 2020 3 Antunes HS et al., "Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients," Radiotherapy and Oncology, 2013 4 Peng J et al., "Low-level laser therapy for oral mucositis: a systematic review and meta-analysis," Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020 5 Campos L et al., "Photobiomodulation in head and neck cancer: a systematic review and meta-analysis," Supportive Care in Cancer, 2020 6 Hu et al., pivotal randomized trial of the MuReva phototherapy system (NCT03972527), Supportive Care in Cancer, 2026 7 Genot-Klastersky MT et al., "Retrospective evaluation of the safety of low-level laser therapy in head and neck cancer patients," Supportive Care in Cancer, 2020 8 Oncology Nursing Society, "Photobiomodulation Shines a New Light on Oral Mucositis Care," ONS Voice, September 2026 9 National Cancer Institute, "Oral Complications of Cancer Therapies (PDQ)"

For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.

This blog was reviewed by Dr. Sourabh Kharait.

This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.

Next
Next

FDA Approves Giredestrant (Wilserdly): A New All-Oral Option When Breast Cancer Outsmarts Hormone Therapy